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Abstract
Background: Treatment with Bacillus Calmette-Guérin (BCG) is the gold standard adjuvant immunotherapy of non-
muscle invasive bladder cancer (NMIBC), although it fails in one third of the patients. NMIBC expresses two tumor-
associated O-linked carbohydrates: the disaccharide (Galβ1,3GalNAc) Thomsen-Friedenreich (T) antigen, and its
sialylated counterpart (Siaα2,3Galβ1,3GalNAc) sialyl-T (sT), synthesized by sialyltransferase ST3GAL1, whose roles in
BCG response are unknown.
Methods: The human bladder cancer (BC) cell line HT1376 strongly expressing the T antigen, was retrovirally
transduced with the ST3GAL1 cDNA or with an empty vector, yielding the cell lines HT1376sT and HT1376T, that
express, respectively, either the sT or the T antigens. Cells were in vitro challenged with BCG. Whole gene expression
was studied by microarray technology, cytokine secretion was measured by multiplex immune-beads assay. Human
macrophages derived from blood monocytes were challenged with the secretome of BCG-challenged BC cells.
Results: The secretome from BCG-challenged HT1376sT cells induced a stronger macrophage secretion of IL-6, IL-1β,
TNFα and IL-10 than that of HT1376T cells. Transcriptomic analysis revealed that ST3GAL1 overexpression and T/sT
replacement modulated hundreds of genes. Several genes preserving genomic stability were down-regulated in
HT1376sT cells which, as a consequence, displayed increased sensitivity to oxidative damage. After BCG challenge, the
transcriptome of HT1376sT cells showed higher susceptibility to BCG modulation than that of HT1376T cells.
Conclusions: High ST3GAL1 expression and T/sT replacement in BCG challenged-BC cancer cells induce a stronger
macrophage response and alter the gene expression towards genomic instability, indicating a potential impact on BC
biology and patient’s response to BCG.
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Background
The intravesical inoculation with the Bacillus Calmette-
Guérin (BCG) is the most effective adjuvant therapy of
non-muscle invasive bladder cancers (NMIBC) after
transurethral resection. However, one third of the
patients fail to respond and experience recurrence after
treatment. The reasons why BCG therapy fail are still
unclear, although it is well established that the anti-
tumor activity of BCG depends on its ability to elicit an
effective local immune response [1–3].
Glycosylation, one of the most frequent post-translational
modification of proteins, undergoes profound changes in all
types of cancer [4], including bladder cancer (BC) [5–8]. The
aberrant expression of glycoconjugates is often caused by the
deranged regulation of their biosynthetic enzymes: the glyco-
syltransferases [9]. The Thomsen-Friedenreich (T) antigen is
a disaccharide (Galβ1,3GalNAc) O-linked to serine or threo-
nine residues of glycoproteins (Additional file 1A), whose
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aberrant expression in cancer has been associated with ma-
lignancy [10–13] and used as a possible target for therapy
[14–16]. Its sialylated counterpart, the sialyl-T (sT) (Siaα2,3-
Galβ1,3GalNAc-O-Ser/Thr) structure and its main biosyn-
thetic enzyme, the sialyltransferase ST3GAL1, are also
aberrantly expressed in a variety of cancers [17, 18]
[reviewed in [19, 20]]. In BC, the expression of T/sT antigens
is also aberrant and it influences invasion and immune rec-
ognition [21–23]. In a previous work [24], we have shown
that the mRNA of ST3GAL1 was overexpressed in NMIBC
but not in muscle invasive BC or in benign bladder tumors
and ST3GAL1 plays the major role in the sialylation of the T
antigen in BC. The T antigen has been suggested as a useful
marker of BCG response [23], even though the relationship
between ST3GAL1/sT and BCG response has never been
established.
In this study, we investigated the effects of the alterna-
tive expression of the T or sT antigens on the ability of
BC cells to activate macrophages in response to BCG
challenge and on the transcriptome of BC cells, utilizing
the HT1376 cell line in which the T antigen was replaced
by the sT antigen, by retroviral transduction with the
ST3GAL1 cDNA. This cell line was chosen because of
its low ST3GAL1 expression and its high and
homogenous reactivity with the T antigen-specific lectin
PNA [24]. The gene expression and cytokine profiles of
the cell lines expressing either the T or the sT antigens
after BCG challenge and the ability of their secretome to
stimulate cytokine release by macrophages was studied.
Methods
Generation of ST3GAL1-expressing cell lines
The HT1376 cell line was established from a primary in-
vasive transitional cell cancer of the bladder [25]. Cells
were grown in DMEM (4.5 g/L glucose, Sigma), contain-
ing 10% foetal calf serum (FCS, Sigma), 2 mM L-glutam-
ine (Sigma) and 100 μg/mL penicillin/streptomycin
(Sigma). HT1376 cells expressing ST3GAL1 were gener-
ated by transduction with a retroviral vector obtained
with the ViraPower Lentiviral Expression System (Invi-
trogen), according to manufacturer’s instructions. The
cDNA of the whole coding region of human ST3GAL1
was obtained by PCR amplification of the cDNA of the
colon cancer cell line HT29 with the following primer
pair: forward primer: 5’-CACCATGGTGACCCTGCG-
GAAGAGG-3′; reverse primer: 5’-TCATCTCCCCTT-
GAAGATCCGG-3′. Amplification was performed for
35 cycles of the following program: denaturation 94 °C
1 min; annealing 60 °C 1 min; extension 72 °C 1 min.
The PCR product was gel isolated and cloned into the
pLenti6/V5 Directional TOPO cloning vector (Invitro-
gen) which drives the expression of inserted genes under
the control of the cytomegalovirus promoter. A negative
control retroviral vector was prepared with an empty
plasmid. After transduction with negative control- or
ST3GAL1-expressing vectors, HT1376 cells were selected
with 4 μg/mL of blasticidin. The replacement of the T
antigen with the sT antigen was evaluated as loss of cell
reactivity with the fluorescent labeled lectin from Arachis
hypogea (peanut agglutinin, PNA), conjugated with fluor-
escein isothiocyanate (PNA-FITC). Although selected cells
were mainly negative to PNA-FITC as detected by FACS
analysis, a small population of PNA-FITC positive cells
was still present. To obtain a population of cells homoge-
neously negative for the T antigen, about 100 ST3GAL1-
transduced HT1376 cells were seeded in a 10 cm Petri
dish and after one month, PNA-FITC negative colonies
were selected and pooled. This polyclonal cell population
homogeneously negative for T antigen expression is there-
after referred to as HT1376sT. The polyclonal cell popula-
tion obtained after transduction with the negative control
retroviral vector followed by blasticidin selection is re-
ferred to as HT1376T.
Flow cytometry
Cells were incubated with PNA-FITC for 30 min at 4 °C
in the dark, washed and analyzed by flow cytometry. Si-
alidase treatment was performed with 20 mU of Clos-
tridium perfringens sialidase (Roche Diagnostics), for
90 min at 37 °C.
Real time RT-PCR
Total RNA was isolated using the GenElute Mammalian
Total RNA Purification kit and DNase treatment
(Sigma), according to the manufacturer’s instructions.
One microgram of total RNA was reverse transcribed,
using the random-primers based High Capacity cDNA
Archive Kit (Applied Biosystems). The expression level
of ST3GAL1 (Hs00161688_m1; NM_173344.2 and
NM_003033.3) was evaluated with the TaqMan assay
system in a 7500 Fast Real-Time PCR System (Applied
Biosystems) using the TaqMan Universal PCR Master
Mix Fast, as previously described [24, 26, 27]. The effi-
ciency of the amplification reaction for each primer-probe
was above 95% (as determined by the manufacturer). Nor-
malized mRNA expression was computed as the number
of mRNA molecules of the gene of interest per 1000
mRNA molecules of the endogenous control β-actin gene,
calculated using the 2-ΔCT×1000 formula [28].
Sialyltransferase activity assay
Cell pellets were homogenized in water and the protein
concentration of the homogenates was determined by
the Lowry method. The activity of ST3GAL1 was
measured in the homogenates in the range of time and
substrate concentration linearity in a 25 μL volume con-
taining: 50 mM of 2-(N-morpholino)ethanesulphonic
acid (MES) buffer pH 6.5, 0.5% Triton X-100, 23.5 μg of
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Galβ1,3GalNAcα1-O-benzyl (benzyl-T; Sigma) as ac-
ceptor substrate, 15 μM (640 Bq) of CMP-[14C]Sia
(Amersham) and 50 μg of homogenate proteins. Reac-
tions were incubated at 37 °C, for 2 h and the products
were then isolated by hydrophobic chromatography in
SepPak C18 Classic Cartridge (Waters). The columns
were washed with water and eluted with 1 mL aceto-
nitrile, which was counted in a liquid scintillation coun-
ter. The incorporation on endogenous substrates, in the
absence of the acceptor substrate, was subtracted.
BCG challenge of HT1376 cells
Commercial Connaught BCG (ImmuCyst, Sanofi Pas-
teur SA, France) was suspended in PBS containing
0.05% Tween 80 and stored at − 80 °C. Before each
assay, BCG aggregates were discarded by centrifugation
(300 × g for 5 min). To assess BCG internalization, bac-
teria were stained with 2 μg/mL of 5-(and-6-)(((4-chlor-
omethyl)benzoyl)amino)tetramethylrhodamine (CMTR,
Invitrogen) for 2 h in culture medium, incubated with
HT1376T or HT1376sT cells in a 1:10 cell/bacteria ratio
for 2 h at 37 °C and analyzed by flow cytometry. To as-
sess cytokine secretion, HT1376T or HT1376sT cells
were challenged with unstained BCG for 2 h at 37 °C,
the medium was removed and the cells were washed
twice with PBS and incubated with fresh medium for
16 h. Conditioned media were used for cytokine analysis
and to challenge macrophages, while cell pellets were
used for RNA extraction and transcriptomic analysis.
Determination of cytokine concentration
The concentration of cytokines IL-1β, IL-2, IL-4, IL-6,
IL-8, IL-10, IL-12, IL-17, IFN-γ and TNF-α was mea-
sured in a 96-well strip plate from a commercial MIBA
kit (Bio-Rad), as recommended by manufacturer’s in-
structions. Fluorescence was read in a Luminex 100 Bio-
Plex Liquid Array Multiplexing System reader (Bio-Rad)
and the data analyzed with the Bio-Plex Manager v5
software (Bio-Rad).
Macrophage preparation and stimulation
Mononuclear cells were isolated by Ficoll-Hypaque
density gradient centrifugation (GE Healthcare) from the
peripheral blood of healthy blood-donors. For this use,
no study approval was necessary. The only authorization
required was that obtained from the Blood Collection
Service of the Pizzardi Hospital in Bologna, Italy, which
keeps the rights on donors’ blood samples. Macrophages
were obtained by differentiation of monocytes by culture
in RPMI 1640 (Sigma) medium supplemented with 20%
FCS, 2 mM L-glutamine and 100 μg/mL penicillin/
streptomycin. After 7 days, monocyte-derived macro-
phages were detached with a cell scraper and dispensed
in 24 well plates at a cell density corresponding
approximately to 50% of confluence. One day later, mac-
rophages were incubated with standard unconditioned
culture medium or with the media conditioned by
HT1376T or HT1376sT cells either BCG-challenged (as
described above) or mock challenged. After 2 h, the con-
ditioned media were replaced by fresh medium, which
was collected 24 h later and stored at − 80 °C for the de-
tection of cytokines secreted by macrophages.
H2O2 treatment
Cells in exponential growth phase were incubated in
serum-free medium containing 5 mM H2O2 for 1 h. The
medium was then replaced with fresh complete medium
and the cells were harvested and analyzed 24 h later.
Mock-treated cells were incubated as above without
H2O2. The cytotoxic effect of H2O2 was determined by
counting the number of cells in six replicas seeded in 6-
wells plates. Representative fields were photographed
with an inverted phase contrast microscope.
Whole transcriptome analysis by expression microarray
Total RNA was isolated by the guanidinium thiocyanate-
method [29] and converted to labelled single strand
cDNA (ssDNA) by the commercial Whole Transcript
Expression kit (Ambion), according to the manufac-
turer’s instructions. Labelled ssDNA fragments were hy-
bridized in a Human Transcriptome Array 2.0 overnight.
After staining with phycoerythrin-streptavidin, fluores-
cence was read in a GeneChip Scanner 3000 7G (Affy-
metrix). After statistical analysis (see below), array data
were functionally analyzed by the ArrayStar v2.0 soft-
ware (DNASTAR) and through a literature search of the
biological roles of modulated genes. Gene nomenclature
followed the HUGO Gene Nomenclature Committee
rules (https://www.genenames.org/) in italic uppercase
letters. With exception of cytokines, proteins had the
same name as the gene, represented in regular
uppercase.
Statistical methods
Microarray raw data were background-subtracted, nor-
malized and summarized with the robust multi-array
average (RMA) algorithm implemented in the Affy pack-
age of Bioconductor (www.bioconductor.org), which uti-
lizes R software. Differentially expressed genes between
query and control assay were selected by application of
the two tail ANOVA, followed by the Benjamini-
Hochberg false discovery rate test with a p or q ≤ 0.05
cut-off and by the log2 expression ratio, considering only
variations ≥0.5. MIBA data were analyzed by ANOVA,
followed by Tukey multiple comparison test. H2O2 tox-
icity data were analyzed by the Student’s t test. The soft-
ware used was Graphpad Prism, version 7.0.
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Results
ST3GAL1-expression leads to replacement of T with sT
antigen in HT1376 cells
The mock-transduced cell line HT1376T, like the wild
type HT1376, expressed high and homogeneous T ex-
pression, while the ST3GAL1-transduced cell line
HT1376sT displayed an homogeneous low PNA reactiv-
ity which could be reverted to high reactivity after sialid-
ase treatment (Additional file 1B). Both the ST3GAL1
activity (Additional file 1C) and the ST3GAL1 mRNA
measured by real time PCR (Additional file 1D) were
very high in HT1376sT although almost undetectable in
HT1376T. The level of ST3GAL1 activity and PNA re-
activity reached by HT1376sT cells was similar to that
displayed by the wild type BC cell line 5637 strongly ex-
pressing ST3GAL1 (data not shown [24]). This is consist-
ent with the notion that, in BC cells, ST3GAL1-mediated
α2,3 sialylation of galactose (Additional file 1A) masks the
T antigen [24].
IL-6 and IL-8 secretion by HT1376T and HT1376sT cells
To assess the effect of ST3GAL1 overexpression and the
consequent replacement of the T with the sT antigen on
cytokine production following BCG stimulation, we
challenged the two HT1376 cell lines with BCG. Among
the several cytokines tested (IL-1β, IL-2, IL-4, IL-6, IL-8,
IL-10, IL-12, IL-17, IFN-γ and TNF-α), only IL-8 was de-
tectable in media conditioned by unchallenged HT1376T or
HT1376sT cells. After BCG challenge, IL-6 became detect-
able in both HT1376sT and HT1376T cells, while the IL-8
secretion showed a clear tendency to up-regulation after
BCG challenge, especially in HT1376T cells (Fig. 1a). The p
values are reported in Additional file 2.
To establish whether the different IL-8 production by
HT1376sT after BCG challenge was due to a higher BCG
uptake by these cells, we measured BCG internalization
by the two HT1376 cell populations by flow cytometry.
As shown in Fig. 1b, there were no significant differ-
ences in the uptake of fluorescent BCG by HT1376T and
HT1376sT cells, ruling out the possibility that differences
in cytokine production by BCG-stimulated HT1376T and
HT1376sT was dependent on different BCG internaliza-
tion rate.
HT1376sT cells induce a stronger macrophage secretory
response after BCG stimuli
To investigate the role played by ST3GAL1 expression
and the consequent T/sT replacement on the stimula-
tion of innate immunity by BCG-challenged BC cells,
the secretion of cytokines by human macrophages stim-
ulated with the secretome of BCG-challenged BC cells
was measured. Unstimulated macrophages secreted high
levels of IL-8 and very low levels of TNF-α, IL-6, IL-1β
and IL-10. This pattern of secretion was not significantly
changed by stimulation with the secretome of BCG-
unchallenged HT1376T or HT1376sT cells (Fig. 2). In
contrast, the secretome from both BCG-challenged cell
lines, in particular that from HT1376sT, significantly in-
creased the secretion of IL-6, IL-1β, TNF-α and IL-10
whereas IL-8 secretion was hardly affected by the secre-
tome of BCG-challenged cells, regardless of their
ST3GAL1 expression (Fig. 2). It should be noted that
the level of secretion of IL-8 and IL-6 by macrophages
was about 10 and 3-fold higher, respectively, than the
level of either in HT1376 cells (Fig. 1), ruling out the
possibility of a significant contamination of cytokines se-
creted by macrophages with those secreted by HT1376
cells. The cytokines IL-2, IL-4, IL-12 and IL-17 were not
secreted by macrophages in any of the tested conditions
(data not shown). The p and q values are reported in
Additional file 2.
HT1376sT cells display down-regulation of genes
preserving genomic stability
The impact of ST3GAL1 overexpression and of T re-
placement by sT on the global transcriptional activity of
HT1376 cells was evaluated by expression microarray
technology. Of the 254 genes, which displayed
ST3GAL1-dependent modulation by at least a log2 ex-
pression ratio ≥ 1.0 (meaning a fold change of at least 2)
with p or q values ≤0.05, 106 were up-regulated and 148
were down-regulated. The complete list of genes
BA
Fig. 1 BCG-stimulation of HT1376 cells. a: Secretion of IL-6 and IL-8.
HT1376T, (white circles) and HT1376sT (black circles) cells were challenged
with BCG for 2 h, then they were washed and cultured in medium for
16 h. Cytokine concentration was determined as described in Materials
and Methods section. Data of three independent experiments are
reported. Statistical analysis is reported in Additional file 2. b: Time course
of BCG uptake. HT1376T (white circles) and HT1376sT (black circles) cells
were challenged with CMTMR-labelled BCG for 2 and 6 h, as described
in the Methods section. BCG internalization was estimated as mean
fluorescence intensity of the cells, measured by flow cytometry Data
of three independent experiments are reported
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showing significant modulation (changes equal or higher
than 2-fold) in HT1376sT vs. HT1376T is reported in
Additional file 3. At least 29 genes putatively regulating
malignancy because of their involvement in the control
of apoptosis, cell growth, angiogenesis, inflammation or
proteolysis, were differentially expressed in HT1376sT
cells, compared with HT1376T cells (Additional file 4). A
search in the literature revealed that 18 genes were mod-
ulated towards increased malignancy and 14 towards de-
creased malignancy (Additional file 4). Remarkably,
among the 18 genes modulated towards increased malig-
nancy in HT1376sT cells, 11 down-regulated genes can
be collectively referred to as “caretaker genes” because
of their involvement in DNA repair and mitotic fidelity
(Additional file 4). Moreover, if threshold was lowered to
include genes down-regulated above 1.3-fold, the num-
ber of down-regulated caretaker genes rose to 34
(Table 1). As a functional validation of gene expression
data, cells were exposed to the genotoxic effects of the
oxidizing agent H2O2. As expected for a cell line with
impaired DNA repair mechanisms, H2O2 -treatment
Fig. 2 Cytokine secretion by human macrophages treated with
conditioned media of BC cell lines. Cytokine secretion was measured
in culture media conditioned by unstimulated macrophages (MΦ,
grey circles) or stimulated with conditioned media from BCG-
challenged or unchallenged BC cell lines: HT1376T, (white circles);
HT1376sT (black circles). Cells were challenged with BCG for 2 h, then
they were washed and allowed to condition the culture medium for
16 h. The conditioned culture media of BCG-challenged or unchallenged
cells was used to stimulate human monocyte-derived macrophages for
24 h. MØ: cytokines released by unstimulated macrophages; MØ+
unchallenged: cytokines released by macrophages stimulated with
the conditioned medium of unchallenged HT1376 cells; MØ+ BCG-
challenged: cytokines released from macrophages stimulated with the
conditioned medium of BCG-challenged cells. Data of three independent
experiments are reported. Statistical analysis is reported in
Additional file 2
Table 1 Genes involved in maintaining chromosomal stability
and/or DNA repair showing down-regulation in HT1376sT cells
Genes showing a fold change ≥ 2 are boxed in gray
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resulted in a reduced viability in HT1376sT than in
HT1376T cells (Fig. 3a and b).
HT1376sT cells display increased transcriptomic changes
after BCG challenging
To investigate the effect of a differential T/sT expression
on BCG challenging, the global transcriptional activity
was also compared in BCG-challenged HT1376T and
HT1376sT cell lines. While in HT1376sT cells a group of
38 genes showed significant modulation by BCG (p and
q values ≤0.05) with a log2 expression ratio ≥ 0.5 (fold
change at least 1.4) (Additional information 5), the ten-
dency to modulation showed by a few genes in HT1376T
cells never reached statistical significance (data not
shown). Modulated genes in HT1376sT cells fell into sev-
eral broad functional categories (Additional information
5). In particular, a set of genes related to “aminoacid and
protein biosynthesis” were prevalently down-regulated in
BCG-challenged HT1376sT cells (Additional file 5). This
functional category includes genes involved in the biosyn-
thesis and transport of aminoacids, attachment of aminoa-
cids to tRNAs and regulation of translation. Other
categories of modulated genes include “cell growth” and
“inflammatory and immune response” (Additional file 5).
Discussion
The overexpression of ST3GAL1 has been widely stud-
ied in cellular models of breast cancer and found to be
responsible for increased malignancy [30–32]. In con-
trast, very little is known on the role of this enzyme in
BC biology. In this work, we have performed an exhaust-
ive analysis of a BC experimental system in which
through the overexpression of ST3GAL1, the constitu-
tively expressed T antigen was replaced by its sialylated
counterpart, the sT carbohydrate structure. Both struc-
tures are biologically active, being receptors either for
galectins or siglecs, as well as for sugar binding recep-
tors of microorganisms [33]. Thus, the phenotypic
changes we report after ST3GAL1 overexpression could
be attributable either to the lack of T antigen or expres-
sion of sT or both. The modulation of the immune re-
sponse, in particular, the secretion of cytokines, is a well
known functional consequence of BCG interaction with
BC cells [1, 34, 35]. Our study confirms that BCG in-
duces IL-6 and IL-8 secretion by BC cells and shows a
tendency to higher IL-8 secretion by BCG-stimulated
cells expressing sT. In BC patients, plasma [36] and tis-
sue [37] IL-6 levels are elevated and associated with
tumor progression and poor prognosis. Previous studies
have indicated that BCG stimulates IL-6 production in
urine of patients and BC cell lines [38], inducing non
apoptotic cell death [39]. Increased urinary IL-8 level
also correlates with progression in BC patients [40], al-
though a high urinary IL-8 level after BCG instillation is
a prognostic factor of successful outcome [41, 42]. Our
data indicate that after BCG challenge, only the secre-
tion of IL-6 and, to a lesser extent, IL-8 were stimulated
while the other cytokines remained undetectable. This is
consistent with clinical observations reporting that a few
cytokines, including IL-6 and IL-8, were detectable in
urine after a first intravesical BCG administration, while
other cytokines required multiple BCG instillations [43].
After BCG challenge, the secretome of BC cells ex-
pressing the sT structure showed higher capacity to
stimulate cytokine secretion by macrophages, further
supporting the notion that the sT antigen potentiates the
BC response to BCG.
An inflammatory environment can either promote or
inhibit tumor progression, consistent with the notion
that inflammation is a double edge sword which can
both eradicate the tumor but also fuel its growth. Mac-
rophages are differentiated either as pro-inflammatory
M1 or anti-inflammatory M2 phenotypes, even if in
many cases they are in an intermediate condition. While
a variable capacity to secrete IL-6, IL-1β and TNF-α is
shared by differentially polarized macrophages, an IL-12
A
B
Fig. 3 Cytotoxic effect of H2O2 on HT1376T and HT1376sT cells. a: cells
were treated with 5 mM H2O2 or mock-treated as described in Methods
and counted. Data of six experiments are reported. The HT1376sT cells
are more susceptible to the toxic effect of H2O2 (**p= 0.005 according to
Student’s t test). b: phase contrast micrograph of representative fields of
the two cell populations treated as described above, showing the
stronger cytotoxic effects of H2O2 on HT1376sT. Scale bar: 100 μm
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low/IL-10 high phenotype is the hallmark of M2 macro-
phages [44], which are known to promote tumor growth
[45]. The macrophages used in this study secreted IL-6,
IL-8, IL-1β and TNF-α but no IL-12 and little IL-10 and
are probably representative of an intermediate condition
between the two extreme phenotypes. The nature of the
macrophages associated with BC is indeed variable as in-
dicated by the different level of expression of the M2-
specific marker CD163 among patients [46]. Interest-
ingly, the predominance of M2 macrophages is associ-
ated with higher stage and grade [46] and with a worse
response to BCG [47].
The most prominent transcriptomic change we ob-
served because of ST3GAL1 expression and the conse-
quent replacement of the T with the sT antigen in
HT1376 cells was the decreased expression of several
genes involved in different mechanisms of DNA repair
and in the accuracy of chromosomal segregation. This
resulted in increased sensitivity of HT1376sT cells to the
cytotoxic effect of H2O2. This is of interest if one con-
siders that the generation of reactive oxygen species by
BCG is a crucial mechanism of BCG-induced damage to
BC cells [48]. Interestingly, also in glioma cells,
ST3GAL1 expression resulted in transcriptomic changes
affecting malignancy and the cell cycle [49], supporting
the notion that a carbohydrate structure on the cell sur-
face can generate an “outside in” flow of information
modulating gene expression [20].
BCG challenge resulted in a deeper modulation of the
transcriptome in HT1376sT than in HT1376T, suggest-
ing that the replacement of the T with the sT antigen on
the cell surface changes the development of the genetic
program triggered by BCG contact.
Even though genes involved in inflammatory and im-
mune response were found to be modulated by BCG
challenge in HT1376sT cells, little or no changes were
observed in genes encoding cytokines, including those
whose expression was stimulated by BCG-challenge. Pos-
sible discrepancies between gene and protein expression
can be explained considering that multiple mechanisms op-
erating at postranscriptional and postranslational levels (in-
cluding non-coding RNAs, translation regulatory
mechanisms, proteasomal activity) regulate protein expres-
sion. In addition, as shown for IL-1β, cytokine secretion
can be regulated by the release of preformed molecules
from intracellular stores, rather than at the level of gene
transcription [50]. The soluble factors responsible for the
stimulation of cytokine secretion by macrophages are con-
ceivably a very complex cocktail of bioactive compounds of
protein and non-protein nature, including biologically ac-
tive molecules (e.g. prostaglandins, glycosaminoglycans)
which are not primary gene products but products of mul-
tiple enzymatic reactions. For these reasons, the nature of
the molecules secreted by BC cells responsible for the effect
on macrophages may not be directly related to the gene ex-
pression profile.
Conclusions
In conclusion, our data show that ST3GAL1 expression
and the consequent replacement of the T by the sT anti-
gen in BC cells induce transcriptomic changes with a
putative impact on multiple cellular functions associated
with increased malignancy and susceptibility to oxidative
damage and strengthens the inflammatory response of
macrophages. This indicates that ST3GAL1 and T/sT
carbohydrate structures can be factors with multiple
clinical implications in BC.
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